Adverum Biotechnologies Inc (ADVM) - News Archive

In an important development for ocular gene therapy, Adverum Biotechnologies, Inc. (Nasdaq: ADVM) has announced the imminent completion of patient screening for its pivotal Phase 3 ARTEMIS trial evaluating Ixo-vec, a gr...

Innovative Advances in Gene Therapy: Adverum Biotechnologies Initiates Pivotal ARTEMIS Phase 3 Study for Wet AMD Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a pioneer in the field of gene therapy, has taken a signific...

In a significant development for investors, Pomerantz LLP has announced its investigation into potential claims on behalf of shareholders of Adverum Biotechnologies, Inc. (NASDAQ: ADVM). The announcement, made on May 9,...

Adverum Biotechnologies Moves to Attract Talent with Inducement Stock Awards Under Nasdaq RegulationsIn a strategic move to bolster its workforce, Adverum Biotechnologies, Inc. (Nasdaq: ADVM) has announced the granting...

Adverum Biotechnologies, Inc. Under Investor Scrutiny Amidst Comparatively Stagnant Performance Pomerantz Law Firm, a highly respected and longstanding authority in securities litigation, has recently announced an inves...

Adverum Biotechnologies Awards Stock Options to New Talent Amid Promising Gene Therapy AdvancesRedwood City, Calif. In a strategic move to attract and retain top-tier talent, Adverum Biotechnologies, Inc. (Nasdaq: ADVM)...

Advancements in Gene Therapy for Wet AMD: Adverum Biotechnologies Sets a New Standard with Ixo-vec In an era where innovative therapies are paramount in managing ocular diseases, Adverum Biotechnologies, Inc. (Nasdaq: A...

Wet age-related macular degeneration (AMD) represents a significant cause of vision impairment and blindness in the older population. Recent advances in gene therapy are promising to reshape the treatment landscape for...

Adverum Biotechnologies Secures FDA RMAT Designation for Ixo-vec, Showcasing Promising Efficacy in Wet AMD Treatment In a significant development within the biotechnology sector, Adverum Biotechnologies, Inc. (Nasdaq: A...

In the field of medical biotechnology, Adverum Biotechnologies (NASDAQ: ADVM) has been making waves with its groundbreaking advancements. With a series of positive developments and promising clinical trial data, the com...

Positive Interim Results from Adverum Biotechnologies’ LUNA Phase 2 Trial Presented at 2024 ASRS Annual Meeting Adverum Biotechnologies recently announced encouraging interim findings from its LUNA Phase 2 clinical tria...

Wet age-related macular degeneration (AMD) is a leading cause of vision loss and impairment in the aging population. Currently, treatment options are limited and often burdensome for patients. However, recent developmen...

Adverum Biotechnologies Financing Raises Questions Amidst Substantial LossesIn recent news, Adverum Biotechnologies Inc, a leading biotech company, has announced a private placement financing of $127.5 million. The fina...